Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695367 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Herniorrhaphy Study for Opioid Elimination
A Phase 2 study, sponsored by Heron Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT03695367 is a Phase 2 study that has completed, run by Heron Therapeutics. The registered enrollment target is 63 participants.
The verdict
NCT03695367, a Phase 2 study, has completed, sponsored by Heron Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label study in subjects undergoing unilateral open inguinal herniorrhaphy.
Interventions
- DRUG Acetaminophen
- DRUG Ibuprofen
- DRUG HTX-011
- DEVICE Vial access device
- DEVICE Luer lock applicator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2018-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03695367
The ClinicalTrials.gov registry entry for NCT03695367 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heron Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Acetaminophen is the first listed.
NCT03695367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03695367 about?
NCT03695367 is a clinical study titled "Phase 2 Herniorrhaphy Study for Opioid Elimination". This is a Phase 2, open-label study in subjects undergoing unilateral open inguinal herniorrhaphy.
What is the current status of trial NCT03695367?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2018-10-01. Estimated completion is 2018-12-15.
What interventions are being tested in trial NCT03695367?
The interventions under investigation include: Acetaminophen (DRUG), Ibuprofen (DRUG), HTX-011 (DRUG), Vial access device (DEVICE), Luer lock applicator (DEVICE).
Who is sponsoring clinical trial NCT03695367?
This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.